Igenica, a biopharmaceutical company founded in 2009, focuses on the development of antibody-based therapies for the treatment of patients with cancer.
Although recombinant monoclonal antibodies (mAbs) are considered to be one of the most promising reagents for immune-based cancer therapy, relatively few products have been approved for use in humans. In fact, there appears to be an increasing reliance on an overlapping portfolio of mAb drugs and drug targets, discovered by a process that has evolved very little over the past two decades. Igenica contends that the key to next generation mAb-based medicines lies in both the identification of new targets and the deployment of novel antibody discovery approaches.
To this end, the company has developed two unique technology platforms that collectively offer a function-orientated screening strategy to systematically discover new tumor antigens and effective antibody drug candidates. The first platform, sTAg (surface-tagged antigen profiling), is an innovative proteomics-based technology designed to identify new surface antigens that are amenable to antibody targeting in cancer settings. The second platform, iTAb (in vivo anti-tumor antibody screening), is a monoclonal antibody discovery platform which provides a function-based,in vivo methodology for screening monoclonal antibody drug candidates against newly discovered antigens that are effective in eliminating or controlling cancer.
863 Mitten Rd., Suite 102
Burlingame, CA 94010
U.S.A.
Web: Igenica, Inc.
